The Brigance Assessment Of Individual Neurodevelopment In Young Children With Sickle Cell Disease- 2
NCT01123863 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 248
Last updated 2018-06-28
Summary
A preliminary study was conducted involving 88 three-year-old children with sickle cell disease (SCD) who were followed at the St. Jude Children's Research Hospital Sickle Cell Center. They were offered developmental screening with the Brigance Preschool Screen-II test during their regular clinic visits from January 2006 to August 2008. Data from this work showed that 50% of 3 year old children with SCD had low developmental screening scores. In addition, the low scores were found to be associated with less parental education and with speech deficits. However they were not associated with sickle cell genotype and hemoglobin level.
The primary goal of this study is to prospectively administer Brigance Preschool Screen -II to 3 year old children with SCD and 3 year old children without SCD who come from similar socioeconomic backgrounds and compare the results between the two groups.
Conditions
Interventions
- OTHER
-
Brigance Preschool Screen -II
Three-year-old children with SCD who are followed at the St. Jude Children's Research Hospital Sickle Cell Center will be offered developmental screening with the Brigance Preschool Screen II during their regular clinic visits. Along with the screening test, socioeconomic data will be collected using a short questionnaire. Families will be asked to participate in this study by allowing us to collect their test results, medical information and socioeconomic data to compare with data collected from the control group. Parents who decline participation in this study will still be offered the Brigance Preschool Screen II as part of their child's clinical care.
- OTHER
-
Brigance Preschool Screen -II
Children in the Control Group will be given the Brigance preschool Screen-II Screening at the daycare they attend. The STARR coordinators have selected four daycare centers that have agreed to serve as control group sites. The family will be asked not to respond or aid the child during the assessment. One parent/guardian will fill out the Socioeconomic Data Collection Form while the examiner works with the child. The screening requires the child to give both verbal and non-verbal responses. The examiner records responses on the Three-Year-Old Child Data Sheet for the Brigance Preschool Screen-II. After the screening is complete the examiner collects the Socioeconomic Data Collection Form from the parent and leaves the room to score the assessment and write recommendations. The examiner then returns to the clinic room to discuss the results with the parent/guardian.
Sponsors & Collaborators
-
St. Jude Children's Research Hospital
lead OTHER
Principal Investigators
-
Jeremie Estepp, MD · St. Jude Children's Research Hospital
Eligibility
- Min Age
- 3 Years
- Max Age
- 4 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-05-31
- Primary Completion
- 2015-05-31
- Completion
- 2015-05-31
Countries
- United States
Study Locations
More Related Trials
-
Impact of Phenylalanine Elevations on Brain and Cognition in Adult PKU Carriers
NCT07220265 ·Status: RECRUITING ·Phase: NA
-
STXBP1 and SYNGAP1 Related Disorders Natural History Study
NCT06555965 ·Status: RECRUITING
-
Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA
NCT05334576 ·Status: UNKNOWN ·Phase: NA
-
The Natural History of Infantile Globoid Cell Leukodystrophy
NCT00983879 ·Status: COMPLETED
-
Mucopolysaccharidosis Type II Natural History
NCT03529786 ·Status: COMPLETED
-
AFQ056 for Language Learning in Children With FXS
NCT02920892 ·Status: COMPLETED ·Phase: PHASE2
-
Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID
NCT00006335 ·Status: COMPLETED
-
Copper Histidine Therapy for Menkes Diseases
NCT00001262 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Baker Gordon Syndrome Natural History Study
NCT06399952 ·Status: RECRUITING
-
Krabbe Disease Global Patient Registry
NCT02993796 ·Status: RECRUITING
-
Natural History Study of Children With Metachromatic Leukodystrophy
NCT01963650 ·Status: TERMINATED
-
The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease
NCT02528617 ·Status: WITHDRAWN ·Phase: PHASE4
-
Biomarker and DNA Collection in Subjects Participating in Protocol 22003
NCT00892580 ·Status: COMPLETED
-
Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001
NCT00823368 ·Status: COMPLETED
-
A Pilot Study to Assess the Feasibility and Acceptability of Newborn Screening Using in Silico Panel-based Solo Genome Sequencing in France
NCT06875089 ·Status: RECRUITING
-
Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics
NCT01675674 ·Status: TERMINATED
-
The Brain and Neuropsychological Functioning in Adults With Sapropterin Dihydrochloride Treated Phenylketonuria
NCT02297347 ·Status: COMPLETED
-
A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases
NCT02633397 ·Status: COMPLETED ·Phase: PHASE2
-
Natural History Studies of Mucopolysaccharidosis III
NCT02037880 ·Status: COMPLETED
-
Natural History of Rett Syndrome & Related Disorders
NCT02738281 ·Status: COMPLETED
-
Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome
NCT07328529 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
AVTX-801 D-galactose Supplementation in SLC35A2-CDG
NCT05402384 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Longitudinal Studies to Identify Biomarkers for Sturge-Weber Syndrome
NCT04717427 ·Status: RECRUITING
-
A Study of Sepiapterin in Participants With Phenylketonuria (PKU)
NCT06302348 ·Status: RECRUITING ·Phase: PHASE3
-
Managed Access Programs for SEG101, Crizanlizumab
NCT03720626 ·Status: AVAILABLE